{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:40:20Z","timestamp":1791193220582,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T00:00:00Z","timestamp":1577318400000},"content-version":"vor","delay-in-days":3891,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1093\/annonc\/mdp143","type":"journal-article","created":{"date-parts":[[2009,5,19]],"date-time":"2009-05-19T06:33:58Z","timestamp":1242714838000},"page":"iv105-iv107","source":"Crossref","is-referenced-by-count":21,"special_numbering":"S4","title":["Chronic myelogenous leukemia: ESMO Clinical Recommendations for diagnosis, treatment and follow-up"],"prefix":"10.1016","volume":"20","author":[{"given":"M.","family":"Baccarani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdp143_bb0010","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp143_bb0015","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u2018good-risk\u2019 chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp143_bb0020","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdp143_bb0025","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdp143_bb0030","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","article-title":"Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia","volume":"109","author":"Hehlmann","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp143_bb0035","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","article-title":"Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials","volume":"108","author":"Roy","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp143_bb0040","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp143_bb0045","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp143_bb0050","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdp143_bb0055","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp143_bb0060","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdp143_bb0065","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR\u2013ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp143_bb0070","first-page":"513","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdp143_bb0075","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1182\/blood-2007-10-118141","article-title":"Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia","volume":"111","author":"Heaney","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp143_bb0080","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR\u2013ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdp143_bb0085","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3324\/haematol.12588","article-title":"Monitoring treatment of chronic myeloid leukemia","volume":"93","author":"Baccarani","year":"2008","journal-title":"Haematologica"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419405590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419405590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/20\/suppl_4\/iv105\/346251\/mdp143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T12:31:07Z","timestamp":1582201867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419405590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":16,"alternative-id":["S0923753419405590"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdp143","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}